Document Detail


Factors that Predict Response of Patients with HCV Infection to Boceprevir.
MedLine Citation:
PMID:  22626609     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND & AIMS: Little is known about factors associated with a sustained virologic response (SVR) among patients with hepatitis C virus (HCV) infection to treatment with protease inhibitors. METHODS: Previously untreated patients (from the SPRINT-2 trial) and those that did not respond to prior therapy (from the RESPOND-2 trial) received either a combination of peginterferon and ribavirin for 48 weeks or boceprevir, peginterferon, and ribavirin (triple therapy) after 4 weeks of peginterferon and ribavirin (total treatment duration 28-48 weeks). A good response to interferon was defined as a ≥1 log(10) decrease in HCV RNA at week 4; a poor response was defined as a <1 log(10) decrease. We used multivariate regression analyses to identify baseline factors of the host (including the polymorphism IL -28B rs12979860) associated with response. The polymorphism IL -28B rs8099917 was also assessed. RESULTS: In the SPRINT-2 trial, factors that predicted a SVR to triple therapy included low viral load (odds ratio [OR]=11.6), IL-28B genotype (rs 12979860 CC vs TT and CT; ORs=2.6 and 2.1), absence of cirrhosis (OR=4.3), HCV subtype 1b (OR=2.0), and non-black race (OR=2.0). In the RESPOND-2 trial, the only factor significantly associated with a SVR was previous relapse, compared with previous non-response (OR=2.6). Most patients with rs12979860 CC who received triple therapy had undetectable levels of HCV RNA by week 8 (76%-89%), and were eligible for shortened therapy. In both studies, IL-28B rs12979860 CC was more strongly associated with a good response to interferon than other baseline factors; however, a ≥1 log(10) decrease in HCV RNA at week 4 was more strongly associated with SVR than IL-28B rs12979860. Combining the rs8099917 and rs12979860 genotypes does not increase the association with SVR. CONCLUSIONS: The CC polymorphism at IL-28B rs12979860 is associated with response to triple therapy and can identify candidates for shorter treatment durations. A ≥1 log(10) decrease in HCV RNA at week 4 of therapy is the strongest predictor of a SVR, regardless of polymorphisms in IL-28B.
Authors:
Fred Poordad; Jean-Pierre Bronowicki; Stuart C Gordon; Stefan Zeuzem; Ira M Jacobson; Mark S Sulkowski; Thierry Poynard; Timothy R Morgan; Cliona Molony; Lisa D Pedicone; Heather L Sings; Margaret H Burroughs; Vilma Sniukiene; Navdeep Boparai; Venkata S Goteti; Clifford A Brass; Janice K Albrecht; Bruce R Bacon;
Related Documents :
22515839 - Risk factors for intestinal invasive amebiasis in japan, 2003-2009.
8444079 - Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of pat...
20161729 - Berberine inhibits hiv protease inhibitor-induced inflammatory response by modulating e...
1446919 - Phagocytosis and microbicidal capacity of human monocytes in the course of hiv infection.
8116259 - Human cytomegalovirus-mediated enhancement of human immunodeficiency virus type-1 produ...
2345809 - The spleen in hiv infection--morphological evidence of hiv-associated macrophage dysfun...
21866279 - Factors associated with utilization of haart amongst hard-to-reach hiv-infected individ...
9014009 - Neutralization of human immunodeficiency virus type 1 (hiv-1) with antibody from carrie...
1647829 - Prevention of cytomegalovirus infection following bone marrow transplantation: a random...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-21
Journal Detail:
Title:  Gastroenterology     Volume:  -     ISSN:  1528-0012     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0374630     Medline TA:  Gastroenterology     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.
Affiliation:
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
Next Document:  Chronic Cadmium Exposure In Vitro Causes Acquisition of Multiple Tumor Cell Characteristics in Human...